Program
risankizumab
Also written as “Risankizumab”, “risankizumab IV” and “risankizumab SC”.
Its studies are mostly in Psoriasis · Crohn Disease · Arthritis, Psoriatic · Colitis, Ulcerative · Arthritis, Juvenile, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 6515 open or running | phase 4since May 28, 2021 | Apr 10, 2012 | Jan 2027phase 1 · NCT07466550 |
| Johnson & Johnson | 21 open or running | phase 3since Mar 23, 2026 | Oct 11, 2021 | Nov 15, 2028phase 3 · NCT07499232 |
| Boehringer Ingelheim | 10 open or running | phase 2since Feb 3, 2014 | Feb 3, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Feb 1, 2016.
- Oct 20, 2023Phase 3 study in Arthritis, JuvenileAbbVie · NCT06100744 · 40 planned · United States, Australia, Canada and more
- Mar 21, 20242 phase 4 studiesAbbVie · NCT06333860, NCT06346288
- Jun 28, 2024Phase 1 study in Healthy VolunteersAbbVie · NCT06487572 · 60 enrolled · United States
- Aug 8, 2024Phase 2 study in Crohn DiseaseAbbVie · NCT06548542 · 590 planned · United States, Austria, Belgium and more
- Aug 23, 2024Phase 1 study in Healthy VolunteersAbbVie · NCT06571266 · 231 enrolled · United States
- Mar 4, 2025Phase 2 study in Arthritis, PsoriaticAbbVie · NCT06865105 · 300 planned · United States, Canada, Czechia and more
- Mar 12, 2025Phase 3 study in Colitis, UlcerativeAbbVie · NCT06880744 · 573 enrolled · United States, Austria, Bulgaria and more
- Apr 4, 20252 phase 1 studiesAbbVie · NCT06937619, NCT06946524
- May 28, 2025Phase 1 study in Healthy VolunteersAbbVie · NCT07007091 · 260 enrolled · United States
- Jul 8, 2025Phase 3 study in Colitis, UlcerativeAbbVie · NCT07071519 · 120 planned · United States, Belgium, Brazil and more
- Mar 9, 2026Phase 1 study in Healthy VolunteerAbbVie · NCT07466550 · 60 planned · United States
- Mar 23, 2026Phase 3 study in Crohn DiseasePhase 3 reachedJohnson & Johnson · NCT07499232 · 530 planned · United States, Austria, Belgium and more
- Jul 7, 2026Phase 2 study in Crohn DiseaseAbbVie · NCT07697456 · 2,000 planned · United States, Canada, Israel and more
- Nov 9, 2026Primary completion moved from 2027-12 to 2029-08Date moved laterphase 2 · +20 months · NCT06865105
Ahead
- Jan 2027Primary completion: phase 1 study in Healthy VolunteerAbbVie · NCT07466550
- Mar 2027Primary completion: phase 3 study in Crohn DiseaseAbbVie · NCT06063967
- Aug 2027Primary completion: phase 3 study in Colitis, UlcerativeAbbVie · NCT06880744
- Feb 2028Primary completion: phase 3 study in Crohn DiseaseAbbVie · NCT04524611
TargetBeta
“Interleukin-23 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| guselkumabrule | Johnson & Johnson | phase 4 | 60 |
| mirikizumabrule | Eli Lilly | phase 4 | 36 |
Studies
The newest 60 of 68 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07697456Crohn Disease · United States, Canada, Israel and more | 2 | Recruiting | AbbVie | Oct 2031 | 2,000 |
| NCT07499232Crohn Disease · United States, Austria, Belgium and more | 3 | Recruiting | Johnson & Johnson | Nov 15, 2028 | 530 |
| NCT07466550Healthy Volunteer · United States | 1 | Recruiting | AbbVie | Jan 2027 | 60 |
| NCT07071519Colitis, Ulcerative · United States, Belgium, Brazil and more | 3 | Recruiting | AbbVie | Jul 2034 | 120 |
| NCT07007091Healthy Volunteers · United States | 1 | Completed | AbbVie | Jan 15, 2026 | 260 |
| NCT06946524Healthy Volunteers · United States | 1 | Completed | AbbVie | Nov 25, 2025 | 59 |
| NCT06937619Healthy Volunteer · United States | 1 | Completed | AbbVie | Nov 10, 2025 | 263 |
| NCT06880744Colitis, Ulcerative · United States, Austria, Bulgaria and more | 3 | Active, not recruiting | AbbVie | Aug 2027 | 573 |
| NCT06865105Arthritis, Psoriatic · United States, Canada, Czechia and more | 2 | Recruiting | AbbVie | Aug 2029 | 300 |
| NCT06571266Healthy Volunteers · United States | 1 | Completed | AbbVie | Apr 16, 2025 | 231 |
| NCT06548542Crohn Disease · United States, Austria, Belgium and more | 2 | Recruiting | AbbVie | Jan 2030 | 590 |
| NCT06487572Healthy Volunteers · United States | 1 | Completed | AbbVie | Feb 7, 2025 | 60 |
| NCT06346288Inflammatory Bowel Diseases · United States, Israel | 4 | Completed | AbbVie | Feb 5, 2026 | 10 |
| NCT06333860Moderate Plaque Psoriasis · United States, Australia, Belgium and more | 4 | Completed | AbbVie | Mar 19, 2026 | 393 |
| NCT06100744Arthritis, Juvenile · United States, Australia, Canada and more | 3 | Recruiting | AbbVie | Sep 2026 | 40 |
| NCT06063967Crohn Disease · United States, Argentina, Brazil and more | 3 | Active, not recruiting | AbbVie | Mar 2027 | 289 |
| NCT06054425Healthy Volunteers · United States | 1 | Completed | AbbVie | May 6, 2024 | 48 |
| NCT05995353Crohn Disease · United States, Belgium, Bulgaria and more | 3 | Recruiting | AbbVie | Apr 2029 | 110 |
| NCT05969223Psoriasis · United States | 4 | Completed | AbbVie | Jan 22, 2025 | 214 |
| NCT05567029Healthy Volunteers · United States | 1 | Completed | AbbVie | Apr 20, 2023 | 198 |
| NCT05305222Healthy Volunteers · United States | 1 | Completed | AbbVie | Jun 15, 2018 | 17 |
| NCT05283694Healthy Volunteers · United States | 1 | Completed | AbbVie | Jun 12, 2018 | 48 |
| NCT05283681Healthy Volunteers · United States | 1 | Completed | AbbVie | Nov 11, 2019 | 226 |
| NCT05274100Healthy Volunteers · United States | 1 | Completed | AbbVie | Jul 6, 2021 | 394 |
| NCT05274087Healthy Volunteers · United States | 1 | Completed | AbbVie | Apr 7, 2021 | 30 |
| NCT05268068Healthy Volunteers · China | 1 | Completed | AbbVie | Apr 26, 2020 | 30 |
| NCT05083078Arthritis, Psoriatic · Austria | 1 | Terminated | Johnson & Johnson | Jul 1, 2022 | 11 |
| NCT04908475Psoriasis · United States, Canada, Germany and more | 4 | Completed | AbbVie | Apr 20, 2023 | 352 |
| NCT04862286Psoriasis · United States, Canada, Germany and more | 3 | Active, not recruiting | AbbVie | Apr 2028 | 132 |
| NCT04713592Psoriasis · United States, Canada, Puerto Rico and more | 3 | Completed | AbbVie | Apr 20, 2023 | 174 |
| NCT04524611Crohn Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Feb 2028 | 527 |
| NCT04451720Psoriasis · Japan | 3 | Completed | AbbVie | Nov 21, 2022 | 119 |
| NCT04435600Psoriasis · United States, Canada, Germany and more | 3 | Completed | AbbVie | Feb 12, 2024 | 139 |
| NCT04254783Colitis, Ulcerative · United States, Germany, Israel | 1 | Completed | AbbVie | Oct 14, 2022 | 20 |
| NCT04102007Plaque Psoriasis · United States, Australia, Germany and more | 3 | Completed | AbbVie | Jan 17, 2022 | 244 |
| NCT03926169Hidradenitis Suppurativa · United States, Australia, Canada and more | 2 | Completed | AbbVie | Feb 2, 2021 | 243 |
| NCT03875508Psoriasis · United States | 3 | Completed | AbbVie | Apr 24, 2020 | 108 |
| NCT03875482Psoriasis · United States, Puerto Rico | 3 | Completed | AbbVie | Feb 20, 2020 | 157 |
| NCT03706040Dermatitis · United States, Australia, Canada and more | 2 | Completed | AbbVie | Oct 28, 2020 | 172 |
| NCT03675308Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Oct 8, 2020 | 964 |
| NCT03671148Arthritis, Psoriatic · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Jun 22, 2020 | 444 |
| NCT03518047Psoriasis · Russian Federation | 3 | Completed | AbbVie | Feb 11, 2020 | 50 |
| NCT03478787Psoriasis · United States, Canada, France and more | 3 | Completed | AbbVie | Jul 8, 2020 | 327 |
| NCT03398148Colitis, Ulcerative · United States, Argentina, Austria and more | 3 | Completed | AbbVie | Nov 9, 2022 | 1,558 |
| NCT03398135Colitis, Ulcerative · United States, Argentina, Austria and more | 3 | Active, not recruiting | AbbVie | Sep 2028 | 1,242 |
| NCT03255382Psoriasis · Germany | 3 | Completed | AbbVie | Jul 6, 2018 | 120 |
| NCT03219437Psoriasis · Brazil | 3 | Completed | AbbVie | Nov 26, 2021 | 104 |
| NCT03105128Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Nov 9, 2020 | 931 |
| NCT03105102Crohn Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Feb 2029 | 1,336 |
| NCT03104413Crohn Disease · United States, Argentina, Australia and more | 3 | Completed | AbbVie | Nov 30, 2020 | 618 |
| NCT03047395Psoriasis · United States, Australia, Austria and more | 3 | Completed | AbbVie | Nov 29, 2023 | 2,170 |
| NCT03022045Psoriasis · Japan | 3 | Completed | AbbVie | Sep 17, 2017 | 18 |
| NCT03000075Psoriasis | 2 | Completed | AbbVie | Sep 21, 2017 | 182 |
| NCT02986373Arthritis, Psoriatic | 2 | Completed | AbbVie | Jul 8, 2018 | 145 |
| NCT02772601Psoriasis · Germany | 1 | Completed | AbbVie | Jun 15, 2017 | 21 |
| NCT02719171Arthritis, Psoriatic | 2 | Completed | AbbVie | May 2017 | 185 |
| NCT02694523Psoriasis | 3 | Completed | AbbVie | Aug 2017 | 684 |
| NCT02684370Psoriasis | 3 | Completed | AbbVie | Dec 2016 | 560 |
| NCT02684357Psoriasis | 3 | Completed | AbbVie | Dec 2016 | 577 |
| NCT02672852Psoriasis | 3 | Completed | AbbVie | Aug 2, 2017 | 507 |
How it is read
Names in the registry
- “Risankizumab”, 53 entries
- “risankizumab”, 17 entries
- “risankizumab IV”, 4 entries
- “risankizumab SC”, 4 entries
- “BI 655066”, 3 entries
Conditions, from the studies’ own filings
- Psoriasis, 25 studies
- Crohn Disease, 11 studies
- Arthritis, Psoriatic, 6 studies
- Colitis, Ulcerative, 5 studies
- Arthritis, Juvenile, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.